# FDA recall D-0239-2023

> **Pharmacy Innovations** · Class II · drug recall initiated 2022-12-22.

## Product

THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/HYDROXYCOBAL 25MG/25MG/25MG/25MG/25MG/20MG/ML (3ML VIAL) INJECTABLE THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/METHYLFOLATE/METHYLCOBAL 10MG/2.5MG/25MG/5MG/5MG/10MG/10MG/ML (1ML VIAL) INJECTABLE THIAMINE/RIBOFLAVIN/NIACINAMIDE/DEXPANTHENOL/PYRIDOXINE 50MG/1MG/100MG/3MG/2MG/ML (30ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.

## Reason for recall

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

## Distribution

Nationwide in the USA

## Key facts

- **Recall number:** D-0239-2023
- **Recalling firm:** Pharmacy Innovations
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2022-12-22
- **Report date:** 2023-02-01
- **Termination date:** 2024-07-31

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Erie, PA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0239-2023

## Citation

> AI Analytics. FDA recall D-0239-2023. Retrieved 2026-06-16 from https://api.ai-analytics.org/recall/D-0239-2023. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*